GNH USA

Europe — EMA

Naglazyme (Galsulfase)

GNH USA supplies Naglazyme (Galsulfase), a enzyme replacement therapy for mucopolysaccharidosis type VI. Request a quote for global supply.

Galsulfase

Request sourcing

1
Pack/s

What is Galsulfase?

Galsulfase, the active ingredient in Naglazyme, is an enzyme replacement therapy presented as a powder for solution for injection for intravenous use. It treats mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) in patients with a deficient N‑acetylgalactosamine‑4‑sulfatase enzyme. GNH USA supplies Naglazyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Galsulfase used for?

Naglazyme is an enzyme replacement therapy used in the management of mucopolysaccharidosis type VI, a lysosomal storage disorder.

- Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): replaces the missing enzyme to reduce dermatan sulfate accumulation. - Patients with deficient N‑acetylgalactosamine‑4‑sulfatase activity: restores enzymatic function within lysosomes. - Long‑term disease management: helps maintain joint mobility, respiratory function and organ health.

What are the side effects of Galsulfase?

Common Side Effects: - Infusion‑related reactions: fever, chills, or flushing. - Gastrointestinal symptoms: nausea, vomiting, or abdominal discomfort. - Headache or dizziness. - Mild urticaria or skin rash.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions. - Significant hepatic enzyme elevation. - Thrombocytopenia or bleeding abnormalities. - Pulmonary hypertension or respiratory distress.

What precautions apply to Galsulfase?

Patients should be monitored closely for infusion reactions and immune responses.

- Monitor for infusion reactions: observe during and after administration. - Assess liver function: periodic testing is recommended. - Check for hypersensitivity: discontinue if severe allergic signs appear. - Avoid use in individuals with known severe allergic reactions to the product. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Galsulfase interact with?

Naglazyme may interact with other therapies that affect immune function or coagulation.

Major Interactions (Avoid): - Concomitant use with other enzyme replacement therapies: may increase risk of immune response. - Live vaccines: may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask infusion‑related reactions. - Immunosuppressants: may alter immune response to the enzyme. - Anticoagulants or antiplatelet agents: monitor bleeding risk.

Frequently asked questions

What is Naglazyme used for?+
Naglazyme is indicated for enzyme replacement therapy in patients with mucopolysaccharidosis type VI (Maroteaux‑Lamy syndrome). It provides the missing N‑acetylgalactosamine‑4‑sulfatase enzyme to reduce the accumulation of dermatan sulfate and help manage disease symptoms.
How does Galsulfase work?+
Galsulfase is a recombinant form of human N‑acetylgalactosamine‑4‑sulfatase. When administered intravenously, it enters cells and restores the enzymatic activity needed to break down dermatan sulfate within lysosomes, thereby decreasing substrate buildup that causes the clinical manifestations of MPS VI.
What is the usual dose of Naglazyme?+
The dose of Naglazyme is individualized. A qualified prescriber determines the amount and frequency based on the patient’s body weight, disease severity, and clinical response. Dosing regimens are not standardized and should follow the prescribing information.
Is Naglazyme safe in pregnancy or breastfeeding?+
Safety of Naglazyme during pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.
How do I order Naglazyme from GNH USA?+
To order Naglazyme, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.
How does Naglazyme compare with other treatments for MPS VI?+
Naglazyme is the only approved enzyme replacement therapy specifically for MPS VI. Other lysosomal storage disease therapies target different enzymes or conditions, so Naglazyme remains the standard of care for patients with deficient N‑acetylgalactosamine‑4‑sulfatase activity.
What are the storage and handling requirements for Naglazyme?+
Naglazyme must be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original container, protect it from light, and avoid freezing or shaking. Once reconstituted, the solution should be used promptly according to the prescribing information.
How is Naglazyme administered?+
Naglazyme is supplied as a sterile powder for solution for injection. The powder is reconstituted with the appropriate diluent and administered by intravenous infusion under medical supervision, typically in a hospital or specialized infusion center.
What are the most serious risks associated with Naglazyme?+
The most serious risks include severe or life‑threatening hypersensitivity reactions such as anaphylaxis, significant hepatic enzyme elevation, and rare hematologic abnormalities like thrombocytopenia. Patients should be monitored closely during and after infusion for any signs of these reactions.
Who should not use Naglazyme?+
Naglazyme is contraindicated in patients with a known severe hypersensitivity to Galsulfase, any component of the formulation, or a history of serious allergic reactions to enzyme replacement therapies. Such individuals should avoid treatment and discuss alternative options with their physician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Galsulfase
Route
Intravenous Use
Manufacturer
Biomarin International Limited
Origin
EU

Related products

Naglazyme 1 mg

Naglazyme 1 mg

Galsulfase · 1 MG

Naglazyme
SOLUTION
BIOMARIN PHARMACEUTICAL INC.
UNITED STATES
Naglazyme

Naglazyme

Galsulfase

Biomarin International Limited
EU
Naglazyme

Naglazyme

Galsulfase

Biomarin International Limited
EU
Naglazyme

Naglazyme

Galsulfase

Biomarin International Limited
EU